News Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
43.9 ^USD	-10.06%		-0.66%	-26.66%

01:51pm	Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating	MT
May. 07	Transcript : Apellis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating	07:51am	MT
Apellis Pharmaceuticals : First Quarter 2024 Earnings Presentation	May. 07	PU
Transcript : Apellis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Apellis Pharmaceuticals Q1 Net Loss Narrows, Revenue Rises	May. 07	MT
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q1 Revenue $172.3M	May. 07	MT
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results	May. 07	GL
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference	May. 06	GL
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting	May. 01	GL
Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $52 From $60, Maintains Neutral Rating	Apr. 29	MT
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment	Apr. 26	MT
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)	Apr. 26	GL
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency	Apr. 26	CI
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results	Apr. 23	GL
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating	Apr. 17	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	Apr. 09	MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM	Apr. 08
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 04	GL
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 01	GL
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	Mar. 21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Summary

Filters